PMID- 29176007
OWN - NLM
STAT- MEDLINE
DCOM- 20171222
LR  - 20171222
IS  - 1732-2693 (Electronic)
IS  - 0032-5449 (Linking)
VI  - 71
IP  - 0
DP  - 2017 Nov 19
TI  - Between biology and medicine: perspectives on the use of dendritic cells in 
      anticancer therapy.
PG  - 921-941
LID - 10.5604/01.3001.0010.5808 [doi]
AB  - Dendritic cells (DCs), as a link between innate and adaptive immunity, play a 
      pivotal role in maintaining homeostasis of the immune system. The DC population 
      is characterized by heterogeneity; it consists of many subpopulations which, 
      despite their phenotypic and localization differences, play an essential function 
      - they are professional antigen presenting cells. Due to their role, DCs can be 
      utilized in a new cancer treatment strategy. Their main purpose is to generate an 
      anticancer response leading to the elimination of cancer cells. The tumor 
      microenvironment, abundant in immunosuppressive factors (e.g. IL-10, TGF-beta, Arg1, 
      IDO), impairs the proper function of DCs. For this reason, various strategies are 
      necessary for ex vivo preparation of DC-based vaccines and for the support of in 
      vivo DCs to fight against tumors. DC-based vaccines are combined with other forms 
      of immunotherapy (e.g. blockade of immune checkpoint molecules, e.g. PD-1 or 
      CTLA-4) or conventional types of therapies (e.g. chemotherapy). Despite the 
      enormous progress that has been made in anticancer therapy in the past two 
      decades, there are still many unresolved issues regarding the effectiveness of 
      the DCs usage. In this paper we described, in both a mouse and a human subject, a 
      series of DC subpopulations, differentiating in normal conditions or under the 
      influence of cancer microenvironment. We listed factors affecting the quality of 
      the in vivo and ex vivo generations of antitumoral responses, significant from a 
      therapeutic point of view. Moreover, the most important strategies for the use of 
      DCs in anticancer therapies, as well as further developments on this field, have 
      been discussed.
FAU - Szczygiel, Agnieszka
AU  - Szczygiel A
AD  - Laboratorium Doswiadczalnej Terapii Przeciwnowotworowej, Instytut Immunologii i 
      Terapii Doswiadczalnej PAN im. L. Hirszfelda we Wroclawiu.
FAU - Pajtasz-Piasecka, Elzbieta
AU  - Pajtasz-Piasecka E
AD  - Laboratorium Doswiadczalnej Terapii Przeciwnowotworowej, Instytut Immunologii i 
      Terapii Doswiadczalnej PAN im. L. Hirszfelda we Wroclawiu.
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Postepy Hig Med Dosw (Online)
JT  - Postepy higieny i medycyny doswiadczalnej (Online)
JID - 101206517
RN  - 0 (IL10 protein, human)
RN  - 0 (Transforming Growth Factor beta)
RN  - 130068-27-8 (Interleukin-10)
SB  - IM
MH  - *Adaptive Immunity
MH  - Animals
MH  - *Dendritic Cells/immunology
MH  - Humans
MH  - *Immunotherapy
MH  - Interleukin-10
MH  - Mice
MH  - Neoplasms/immunology/*therapy
MH  - Transforming Growth Factor beta
OTO - NOTNLM
OT  - DC subsets
OT  - DC-based vaccines
OT  - DC;s
OT  - anticancer immunotherapy
OT  - dendritic cells
EDAT- 2017/11/28 06:00
MHDA- 2017/12/23 06:00
CRDT- 2017/11/28 06:00
PHST- 2017/11/28 06:00 [entrez]
PHST- 2017/11/28 06:00 [pubmed]
PHST- 2017/12/23 06:00 [medline]
AID - 01.3001.0010.5808 [pii]
AID - 10.5604/01.3001.0010.5808 [doi]
PST - ppublish
SO  - Postepy Hig Med Dosw (Online). 2017 Nov 19;71(0):921-941. doi: 
      10.5604/01.3001.0010.5808.